Administration of high-dose aprotinin during nonprimary cardiovascular surgery: Case reports and review of the literature

Charles W. Whitten, Paul M. Allison, Lisa M. Morse, Terry W. Latson

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The perioperative management of two patients undergoing complex "redo" cardiac surgical procedures are presented. The management of both patients included the prophylactic administration of aprotinin via a "compassionate use" protocol. Aprotinin, a serine protease inhibitor, has been shown to limit the exposure to blood and blood products in patients undergoing high-risk cardiac surgical procedures. In late December 1993, the Food and Drug Administration approved aprotinin for administration to cardiac surgical patients considered at high risk for post-cardiopulmonary bypass coagulopathies. Indications for the administration of aprotinin, as well as a brief review of the literature relating to the perioperative administration of aprotinin, are included.

Original languageEnglish (US)
Pages (from-to)515-520
Number of pages6
JournalJournal of Clinical Anesthesia
Volume6
Issue number6
DOIs
StatePublished - 1994

Fingerprint

Aprotinin
Cardiac Surgical Procedures
Compassionate Use Trials
Serine Proteinase Inhibitors
United States Food and Drug Administration
Cardiopulmonary Bypass

Keywords

  • Aprotinin
  • cardiopulmonary bypass
  • hemostasis
  • surgery, cardiac

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Administration of high-dose aprotinin during nonprimary cardiovascular surgery : Case reports and review of the literature. / Whitten, Charles W.; Allison, Paul M.; Morse, Lisa M.; Latson, Terry W.

In: Journal of Clinical Anesthesia, Vol. 6, No. 6, 1994, p. 515-520.

Research output: Contribution to journalArticle

@article{7049434286364cdbbda0a5566214fe08,
title = "Administration of high-dose aprotinin during nonprimary cardiovascular surgery: Case reports and review of the literature",
abstract = "The perioperative management of two patients undergoing complex {"}redo{"} cardiac surgical procedures are presented. The management of both patients included the prophylactic administration of aprotinin via a {"}compassionate use{"} protocol. Aprotinin, a serine protease inhibitor, has been shown to limit the exposure to blood and blood products in patients undergoing high-risk cardiac surgical procedures. In late December 1993, the Food and Drug Administration approved aprotinin for administration to cardiac surgical patients considered at high risk for post-cardiopulmonary bypass coagulopathies. Indications for the administration of aprotinin, as well as a brief review of the literature relating to the perioperative administration of aprotinin, are included.",
keywords = "Aprotinin, cardiopulmonary bypass, hemostasis, surgery, cardiac",
author = "Whitten, {Charles W.} and Allison, {Paul M.} and Morse, {Lisa M.} and Latson, {Terry W.}",
year = "1994",
doi = "10.1016/0952-8180(94)90096-5",
language = "English (US)",
volume = "6",
pages = "515--520",
journal = "Journal of Clinical Anesthesia",
issn = "0952-8180",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Administration of high-dose aprotinin during nonprimary cardiovascular surgery

T2 - Case reports and review of the literature

AU - Whitten, Charles W.

AU - Allison, Paul M.

AU - Morse, Lisa M.

AU - Latson, Terry W.

PY - 1994

Y1 - 1994

N2 - The perioperative management of two patients undergoing complex "redo" cardiac surgical procedures are presented. The management of both patients included the prophylactic administration of aprotinin via a "compassionate use" protocol. Aprotinin, a serine protease inhibitor, has been shown to limit the exposure to blood and blood products in patients undergoing high-risk cardiac surgical procedures. In late December 1993, the Food and Drug Administration approved aprotinin for administration to cardiac surgical patients considered at high risk for post-cardiopulmonary bypass coagulopathies. Indications for the administration of aprotinin, as well as a brief review of the literature relating to the perioperative administration of aprotinin, are included.

AB - The perioperative management of two patients undergoing complex "redo" cardiac surgical procedures are presented. The management of both patients included the prophylactic administration of aprotinin via a "compassionate use" protocol. Aprotinin, a serine protease inhibitor, has been shown to limit the exposure to blood and blood products in patients undergoing high-risk cardiac surgical procedures. In late December 1993, the Food and Drug Administration approved aprotinin for administration to cardiac surgical patients considered at high risk for post-cardiopulmonary bypass coagulopathies. Indications for the administration of aprotinin, as well as a brief review of the literature relating to the perioperative administration of aprotinin, are included.

KW - Aprotinin

KW - cardiopulmonary bypass

KW - hemostasis

KW - surgery, cardiac

UR - http://www.scopus.com/inward/record.url?scp=0028580682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028580682&partnerID=8YFLogxK

U2 - 10.1016/0952-8180(94)90096-5

DO - 10.1016/0952-8180(94)90096-5

M3 - Article

C2 - 7533505

AN - SCOPUS:0028580682

VL - 6

SP - 515

EP - 520

JO - Journal of Clinical Anesthesia

JF - Journal of Clinical Anesthesia

SN - 0952-8180

IS - 6

ER -